Bio-Rad Laboratories, Inc. develops, manufactures, and markets a broad range of products and solutions for the life science research and clinical diagnostics markets. Technologies and applications include electrophoresis, imaging, multiplex immunoassay, chromatography, microbiology, protein function analysis, transfection, flow cytometry and cell sorting, amplification, and real-time and digital PCR.
Bio-Rad is an in-vitro diagnostics supplier, delivering a large portfolio of innovative products to clinical laboratories worldwide. Also the Company is a leader in clinical quality control products, services, and information systems. These products ensure the accuracy and validity of clinical test results and are used by more clinical laboratories than products from any other company. Its other diagnostic products and systems leverage a broad range of technologies and deliver high-value clinical 
information in the blood transfusion, diabetes monitoring, autoimmune, and infectious disease testing markets and are used to support the diagnosis, monitoring, and treatment of diseases and other medical conditions.

Company Growth (employees)
Hercules, US
Size (employees)
8,250 (est)+7%
Bio-Rad was founded in 1952 and is headquartered in Hercules, US

Bio-Rad Office Locations

Bio-Rad has an office in Hercules
Hercules, US (HQ)
1000 Alfred Nobel Dr
Hercules, US
4000 Alfred Nobel Dr
Hercules, US
2000 Alfred Nobel Dr

Bio-Rad Data and Metrics

Bio-Rad Financial Metrics

Bio-Rad's revenue was reported to be $2.1 b in FY, 2016 which is a 2% increase from the previous period.

Revenue (FY, 2016)

2.1 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

1.1 b

Gross profit margin (FY, 2016), %


EBIT (FY, 2016)

53.2 m

Market capitalization (20-Jul-2017)

6.9 b

Closing share price (20-Jul-2017)


Cash (31-Dec-2016)

456.3 m
Bio-Rad's current market capitalization is $6.9 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


2.1 b2.2 b2 b2.1 b

Revenue growth, %


Cost of goods sold

897.8 m930.1 m

Gross profit

1.1 b1.1 b

Gross profit Margin, %



166.7 m53.2 m

EBIT margin, %


Pre tax profit

145.8 m41.6 m

Net Income

77.8 m88.8 m113.1 m
USDFY, 2013FY, 2014FY, 2015FY, 2016


331.6 m413.3 m457.5 m456.3 m


525 m

Current Assets

1.7 b1.7 b1.8 b1.8 b


429.4 m428.8 m437.7 m488.6 m

Total Assets

3.4 b3.3 b3.7 b3.9 b

Accounts Payable

148.5 m128.6 m122.4 m133.1 m

Current Liabilities

487.5 m446.8 m441.4 m471.3 m

Total Liabilities

1.3 b

Common Stock

2 k2 k2 k2 k

Additional Paid-in Capital

240 m271.3 m300.4 m332.9 m

Retained Earnings

1.6 b1.7 b1.8 b1.8 b

Total Equity

2.2 b2.2 b2.5 b2.6 b

Financial Leverage

1.5 x1.5 x1.5 x1.5 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

77.8 m88.8 m113.1 m

Cash From Operating Activities

175.5 m273.3 m186.2 m216.4 m

Capital Expenditures

(113 m)(121 m)(112 m)(141.4 m)

Cash From Investing Activities

(5.4 m)(190.5 m)(166.9 m)(213.9 m)

Cash From Financing Activities

(311.7 m)11.7 m8.6 m9 m

Interest Paid

(61.2 m)(20.8 m)(20.8 m)(21.3 m)

Free Cash Flow

288.5 m394.3 m298.2 m75 m
Y, 2016

Financial Leverage

1.5 x

Bio-Rad Market Value History

Bio-Rad Online and Social Media Presence

Bio-Rad Company Life and Culture

You may also be interested in